Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Tue, Mar 18, 2025
[Archive]
Volume 16, Issue 2 (Spring 2025)
Caspian J Intern Med 2025, 16(2): 198-214 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahrampour Juybari K, Shamsi meymandi M, Bashiri H. Effects of colchicine, interferon β, IVIG, tocilizumab and corticosteroids on COVID-19 patient survival from all presently available published clinical trials: A narrative review. Caspian J Intern Med 2025; 16 (2) :198-214
URL: http://caspjim.com/article-1-4015-en.html
URL: http://caspjim.com/article-1-4015-en.html
Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran , bashiry_h@yahoo.com
Abstract: (331 Views)
One of the deadliest diseases in the world, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing global pandemic known as COVID-19. COVID-19 symptoms range from undetectable to deadly, hyper-inflammatory response and the overproduction of pro-inflammatory cytokines or hypercytokinemia are key factors in the pathophysiology of severe COVID-19. However, no specific and effective treatment was available, anti-inflammatory drugs have been vastly used for treating patients. The goal of this narrative literature review (2020–2022) was to elucidate the connection between anti-inflammatory medications and COVID-19 outcomes, such as safety and survival rate. Overall, these studies are consistent in presenting that anti-inflammatory drug can be advised to target the host immune response in patients and have been beneficial in reducing the mortality rate. This is revealed in current recommendations from prominent global public health authorities, which support anti-inflammatory drug use for a decrease of cytokine storm during COVID-19.
Keywords: COVID-19, Colchicine, Interferon β, IVIG, Tocilizumab, Corticosteroids, Anti-inflammatory drugs
Type of Study: Review Article |
Subject:
pharmacology
Received: 2023/07/16 | Accepted: 2024/03/6 | Published: 2025/03/11
Received: 2023/07/16 | Accepted: 2024/03/6 | Published: 2025/03/11
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
